Cargando…
Assessment of efficacy and impact on work productivity and attendance after a mandatory switch to generic second-generation antihistamines: results of a patient survey in Norway
BACKGROUND: In 2006, the Norwegian Medicines Agency mandated a switch from desloratadine, ebastine, or fexofenadine to cetirizine or loratadine in patients with allergic rhinitis (AR) or chronic urticaria (CU). In an online survey, patients whose medication was switched assessed the impact on effica...
Autores principales: | Thorn, Fredrik, Celius, Halvor, Ødegård, Tone, Mandla, Randeep, Hexeberg, Erik |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3053265/ https://www.ncbi.nlm.nih.gov/pubmed/21356091 http://dx.doi.org/10.1186/1476-7961-9-5 |
Ejemplares similares
-
Balanced discussion of second-generation antihistamines’ data
por: Boev, Rossen, et al.
Publicado: (2016) -
Antihistaminic, Anti-Inflammatory, and Antiallergic Properties of the Nonsedating Second-Generation Antihistamine Desloratadine: A Review of the Evidence
por: Canonica, G. Walter, et al.
Publicado: (2011) -
Pathobiology of Second-Generation Antihistamines Related to Sleep in Urticaria Patients
por: Mann, Caroline, et al.
Publicado: (2022) -
Stroke unit demand in Norway – present and future estimates
por: Dahl, Fredrik A., et al.
Publicado: (2022) -
Aspects of Equality in Mandatory Partnerships – From the
Perspective of Municipal Care in Norway
por: Kirchhoff, Ralf, et al.
Publicado: (2016)